An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TARGET3D
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Planned number of patients changed from 60 to 90.
- 07 Jun 2017 Planned End Date changed from 1 Apr 2019 to 1 Dec 2022.